pubmed.ncbi.nlm.nih.gov

Cardioproteomics: advancing the discovery of signaling mechanisms involved in cardiovascular diseases - PubMed

Cardioproteomics: advancing the discovery of signaling mechanisms involved in cardiovascular diseases

Ziyou Cui et al. Am J Cardiovasc Dis. 2011.

Abstract

Cardioproteomics (Cardiovascular proteomics) is fast becoming an indispensible technique in deciphering changes in signaling pathways that occur in cardiovascular diseases (CVDs). The quality and availability of the instruments and bioinformatics software used for cardioproteomics continues to improve, and these techniques are now available to most cardiovascular researchers either directly or indirectly via university core centers. The heart and aorta are specialized tissues which present unique challenges to investigate. Currently, the diverse range of proteomic techniques available for cardiovascular research makes the choice of the best method or best combination of methods for the disease parameter(s) being investigated as important as the equipment used. This review focuses on proteomic techniques and their applications which have advanced our understanding of the signaling mechanisms involved in CVDs at the levels of protein complex/protein-protein interaction, post-translational modifications and signaling induced protein changes.

Keywords: Cardioproteomics; cardiovascular diseases; drug signaling; heart; mass spectrometry; proteomics; signaling pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Schematic of the typical Proteomic workflow for sample processing and mass spectrometry-based identification of a protein. Trypsin digestion (either in-gel or in-solution) occurs between protein and peptide fractionation.

Figure 2
Figure 2

Schematic diagram showing a specific phosphorylation related cardiovascular signaling pathway involving tropomyosin which was partly resolved by cardioproteomics. A mutation in tropomyosin (E54K) is associated with dilated cardiomyopathy and this mutation was investigated using transgenic mice expressing this mutant protein [44]. Proteomics revealed that decreased phosphorylation of tropomyosin may directly affect myofilament function and be part of the dilated cardiomyopathy signaling pathway in E54K transgenic mice.

Similar articles

Cited by

References

    1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209. - PMC - PubMed
    1. Arrell DK, Neverova I, Van Eyk JE. Cardiovascular proteomics: evolution and potential. Circ Res. 2001;88:763–773. - PubMed
    1. Ping P. Identification of novel signaling complexes by functional proteomics. Circ Res. 2003;93:595–603. - PubMed
    1. Agnetti G, Husberg C, Van Eyk JE. Divide and conquer: the application of organelle proteomics to heart failure. Circ Res. 2011;108:512–526. - PMC - PubMed
    1. Ping P, Chan DW, Srinivas P. Advancing cardiovascular biology and medicine via proteomics: Opportunities and present challenges of cardiovascular proteomics. Circulation. 2010;121:2326–2328. - PMC - PubMed

LinkOut - more resources